Can-Fite Secures Brazilian Patent for A3 Adenosine Receptor Agonists in Sexual Dysfunction Treatment
核心洞察
Can-Fite BioPharma received Brazilian patent protection for using A3 adenosine receptor agonists to treat sexual dysfunction, expanding its intellectual property portfolio in Latin America's largest pharmaceutical market.
The patent is based on preclinical and clinical data suggesting A3 adenosine receptor activation can modulate key signaling mechanisms involved in erectile and sexual function through vascular, inflammatory, and metabolic pathways.
This intellectual property milestone strengthens Can-Fite's position for potential partnering and commercialization opportunities while validating the therapeutic versatility of its A3AR agonist platform across multiple medical conditions.
Can-Fite BioPharma Ltd. announced that the Brazilian Patent Office (INPI) has granted Patent No. BR112015002697-4, entitled "Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction." The biotechnology company, which trades on NYSE American and TASE under the symbol CANF, develops proprietary small-molecule drugs targeting oncological and inflammatory diseases.
The granted patent provides intellectual-property protection in Brazil for the use of Can-Fite's proprietary A3AR agonists in treating sexual dysfunction, further strengthening the company's global patent portfolio. Brazil represents one of the largest pharmaceutical markets in Latin America, with growing demand for innovative therapies addressing sexual health conditions.
Scientific Rationale and Clinical Evidence
Sexual dysfunction is associated with vascular, inflammatory, and metabolic pathways. Preclinical and clinical data generated by Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms involved in erectile and sexual function, supporting the therapeutic rationale underlying the patent.
"The grant of this Brazilian patent further validates the therapeutic versatility of A3 adenosine receptor agonists and expands our intellectual-property footprint in a major pharmaceutical market," said Pnina Fishman, Ph.D., Chairperson and Chief Scientific Officer of Can-Fite BioPharma. "This patent complements our broader clinical and preclinical programs and may create future partnering or commercialization opportunities in Latin America."
Broader Pipeline Development
Can-Fite continues to advance its A3AR agonist platform across multiple indications, including oncology, inflammatory diseases, and additional non-oncologic conditions, while actively evaluating strategic opportunities to maximize the value of its patent estate.
The company's lead drug candidate, Piclidenoson, reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer.
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. The compound has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
Safety Profile and Clinical Experience
CF602, the company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date, according to the company.